The biopharmaceutical sector has exhibited strong momentum in recent years, driven by government initiatives to modernize the drug regulatory pathway and higher investments in research and development. Also, the COVID-19 has proven to be a catalyst for the sector’s growth. Now that biotech innovation is perceived more clearly as critical to worldwide human health, we think top players Gilead Sciences (GILD) and Biogen (BIIB) should see sustained demand for their products to their valuation benefit. But let’s find out which of these stocks is a better buy now.
Business, Services And Guides For Music Labels